JPH05194260A - ペプチド組成物 - Google Patents

ペプチド組成物

Info

Publication number: JPH05194260A
Authority: JP; Japan
Prior art keywords: pharmaceutical composition; acid; lys; composition according; salt
Prior art date: 1991-07-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP4186621A

Other languages

English (en)

Japanese (ja)

Inventor

Azria Moise

ムワズ・アズリア

Gert Fricker

ゲルト・フリッカー

Jacky Vonderscher

ジャッキー・フォンデルシェール

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sandoz AG

Original Assignee

Sandoz AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-07-15

Filing date

1992-07-14

Publication date

1993-08-03

1991-07-15 Priority claimed from GB919115202A external-priority patent/GB9115202D0/en

1992-01-14 Priority claimed from GB929200748A external-priority patent/GB9200748D0/en

1992-07-14 Application filed by Sandoz AG filed Critical Sandoz AG

1993-08-03 Publication of JPH05194260A publication Critical patent/JPH05194260A/ja

Status Pending legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title description 58
108090000765 processed proteins & peptides Proteins 0.000 title description 4
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 35
230000000694 effects Effects 0.000 claims abstract description 29
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims abstract description 27
-1 isocaproyl Chemical group 0.000 claims abstract description 24
102000055006 Calcitonin Human genes 0.000 claims abstract description 11
108060001064 Calcitonin Proteins 0.000 claims abstract description 11
229960004015 calcitonin Drugs 0.000 claims abstract description 11
241000972773 Aulopiformes Species 0.000 claims abstract 2
235000019515 salmon Nutrition 0.000 claims abstract 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 41
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 39
150000003839 salts Chemical class 0.000 claims description 35
239000003613 bile acid Substances 0.000 claims description 22
RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 18
229960001091 chenodeoxycholic acid Drugs 0.000 claims description 17
239000002253 acid Substances 0.000 claims description 16
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 15
241000282560 Macaca mulatta Species 0.000 claims description 15
WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 claims description 14
RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims description 14
239000007788 liquid Substances 0.000 claims description 11
238000005303 weighing Methods 0.000 claims description 11
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
239000008280 blood Substances 0.000 claims description 9
210000004369 blood Anatomy 0.000 claims description 9
229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
239000008108 microcrystalline cellulose Substances 0.000 claims description 9
150000001413 amino acids Chemical class 0.000 claims description 8
150000001875 compounds Chemical class 0.000 claims description 7
238000000034 method Methods 0.000 claims description 6
239000007787 solid Substances 0.000 claims description 6
229910052751 metal Inorganic materials 0.000 claims description 5
239000002184 metal Substances 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 5
239000004472 Lysine Substances 0.000 claims description 4
229960000686 benzalkonium chloride Drugs 0.000 claims description 4
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 4
238000002156 mixing Methods 0.000 claims description 3
230000001737 promoting effect Effects 0.000 claims description 2
WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 claims 1
239000011575 calcium Substances 0.000 abstract description 19
229910052791 calcium Inorganic materials 0.000 abstract description 19
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 17
229940126062 Compound A Drugs 0.000 description 52
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 52
235000002639 sodium chloride Nutrition 0.000 description 34
239000003623 enhancer Substances 0.000 description 18
229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 16
108010068072 salmon calcitonin Proteins 0.000 description 16
230000009103 reabsorption Effects 0.000 description 14
WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 14
239000002775 capsule Substances 0.000 description 13
239000000243 solution Substances 0.000 description 12
229920002472 Starch Polymers 0.000 description 11
235000019698 starch Nutrition 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
230000036470 plasma concentration Effects 0.000 description 10
239000008107 starch Substances 0.000 description 10
239000004480 active ingredient Substances 0.000 description 9
235000010980 cellulose Nutrition 0.000 description 9
229920002678 cellulose Polymers 0.000 description 9
KDXKERNSBIXSRK-UHFFFAOYSA-M lysinate Chemical compound NCCCCC(N)C([O-])=O KDXKERNSBIXSRK-UHFFFAOYSA-M 0.000 description 9
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
239000004005 microsphere Substances 0.000 description 7
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
229910001424 calcium ion Inorganic materials 0.000 description 6
239000008101 lactose Substances 0.000 description 6
229960003646 lysine Drugs 0.000 description 6
239000000902 placebo Substances 0.000 description 6
229940068196 placebo Drugs 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
159000000000 sodium salts Chemical class 0.000 description 6
239000007921 spray Substances 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
239000001913 cellulose Substances 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
239000003814 drug Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
229920002307 Dextran Polymers 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
239000000969 carrier Substances 0.000 description 4
229920001577 copolymer Polymers 0.000 description 4
229940079593 drug Drugs 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
210000002850 nasal mucosa Anatomy 0.000 description 4
210000002784 stomach Anatomy 0.000 description 4
238000012360 testing method Methods 0.000 description 4
239000004375 Dextrin Substances 0.000 description 3
229920001353 Dextrin Polymers 0.000 description 3
208000001132 Osteoporosis Diseases 0.000 description 3
IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 3
230000009102 absorption Effects 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
230000004913 activation Effects 0.000 description 3
150000001447 alkali salts Chemical class 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
235000019425 dextrin Nutrition 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
230000001184 hypocalcaemic effect Effects 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
210000003928 nasal cavity Anatomy 0.000 description 3
239000002245 particle Substances 0.000 description 3
238000003359 percent control normalization Methods 0.000 description 3
229920000747 poly(lactic acid) Polymers 0.000 description 3
239000004626 polylactic acid Substances 0.000 description 3
229920002689 polyvinyl acetate Polymers 0.000 description 3
239000011118 polyvinyl acetate Substances 0.000 description 3
WDFRNBJHDMUMBL-OICFXQLMSA-M sodium;(4r)-4-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)CC1 WDFRNBJHDMUMBL-OICFXQLMSA-M 0.000 description 3
239000008247 solid mixture Substances 0.000 description 3
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
239000004380 Cholic acid Substances 0.000 description 2
229920000858 Cyclodextrin Polymers 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
208000013038 Hypocalcemia Diseases 0.000 description 2
208000010191 Osteitis Deformans Diseases 0.000 description 2
208000027868 Paget disease Diseases 0.000 description 2
229920002230 Pectic acid Polymers 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
239000002585 base Substances 0.000 description 2
150000001669 calcium Chemical class 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000019416 cholic acid Nutrition 0.000 description 2
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
229960002471 cholic acid Drugs 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
229920002674 hyaluronan Polymers 0.000 description 2
229960003160 hyaluronic acid Drugs 0.000 description 2
230000000705 hypocalcaemia Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
208000027202 mammary Paget disease Diseases 0.000 description 2
210000000214 mouth Anatomy 0.000 description 2
LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 2
229920000058 polyacrylate Polymers 0.000 description 2
239000010318 polygalacturonic acid Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000004044 response Effects 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical class OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
MFKNWILXUPXSJS-UHFFFAOYSA-M C(C=1C(S)=CC=CC1)(=O)[O-].C[Hg].[Na+] Chemical compound C(C=1C(S)=CC=CC1)(=O)[O-].C[Hg].[Na+] MFKNWILXUPXSJS-UHFFFAOYSA-M 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
108010076119 Caseins Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
229920000896 Ethulose Polymers 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
239000001116 FEMA 4028 Substances 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
229920002581 Glucomannan Polymers 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010007979 Glycocholic Acid Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
150000000994 L-ascorbates Chemical class 0.000 description 1
RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
229920000805 Polyaspartic acid Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010020346 Polyglutamic Acid Proteins 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000004373 Pullulan Substances 0.000 description 1
229920001218 Pullulan Polymers 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
101100229953 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SCT1 gene Proteins 0.000 description 1
101100194362 Schizosaccharomyces pombe (strain 972 / ATCC 24843) res1 gene Proteins 0.000 description 1
241000978776 Senegalia senegal Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
229940124532 absorption promoter Drugs 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
150000001323 aldoses Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229960002749 aminolevulinic acid Drugs 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960003121 arginine Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
NGPGDYLVALNKEG-UHFFFAOYSA-N azanium;azane;2,3,4-trihydroxy-4-oxobutanoate Chemical compound [NH4+].[NH4+].[O-]C(=O)C(O)C(O)C([O-])=O NGPGDYLVALNKEG-UHFFFAOYSA-N 0.000 description 1
229960001716 benzalkonium Drugs 0.000 description 1
CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229960004853 betadex Drugs 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000008859 change Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
235000013305 food Nutrition 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
229940046240 glucomannan Drugs 0.000 description 1
150000002302 glucosamines Chemical class 0.000 description 1
239000008103 glucose Substances 0.000 description 1
RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
229940099347 glycocholic acid Drugs 0.000 description 1
229940074774 glycyrrhizinate Drugs 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000001341 hydroxy propyl starch Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
235000013828 hydroxypropyl starch Nutrition 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
208000030915 hypercalcemia disease Diseases 0.000 description 1
230000006872 improvement Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
239000013081 microcrystal Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000004677 mucosal permeability Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229940067631 phospholipid Drugs 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
235000002949 phytic acid Nutrition 0.000 description 1
229940068041 phytic acid Drugs 0.000 description 1
239000000467 phytic acid Substances 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
108010064470 polyaspartate Proteins 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
108010094020 polyglycine Proteins 0.000 description 1
229920000232 polyglycine polymer Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
108010050934 polyleucine Proteins 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
150000004804 polysaccharides Chemical class 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
235000019423 pullulan Nutrition 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
150000003902 salicylic acid esters Chemical class 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
MOCOXAJEZKHXSF-IHMBCTQLSA-M sodium;(2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound [Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MOCOXAJEZKHXSF-IHMBCTQLSA-M 0.000 description 1
FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229960004906 thiomersal Drugs 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
238000002627 tracheal intubation Methods 0.000 description 1
RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
229960001661 ursodiol Drugs 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Obesity (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

JP4186621A 1991-07-15 1992-07-14 ペプチド組成物 Pending JPH05194260A (ja)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB919115202A GB9115202D0 (en)	1991-07-15	1991-07-15	Improvements relating to organic compounds
GB929200748A GB9200748D0 (en)	1992-01-14	1992-01-14	Improvements relating to organic compounds
GB9115202		1992-01-14
GB9200748		1992-01-14

Publications (1)

Publication Number	Publication Date
JPH05194260A true JPH05194260A (ja)	1993-08-03

Family

ID=26299234

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP4186621A Pending JPH05194260A (ja)	1991-07-15	1992-07-14	ペプチド組成物

Country Status (7)

Country	Link
JP (1)	JPH05194260A (fr)
BE (1)	BE1007752A5 (fr)
CH (1)	CH685600A5 (fr)
DE (1)	DE4222647A1 (fr)
FR (1)	FR2682598B1 (fr)
GB (1)	GB2257908B (fr)
IT (1)	IT1263222B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6228836B1 (en)	1997-04-14	2001-05-08	Mitsubishi-Tokyo Pharmaceuticals, Inc.	Permucous preparation

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5698521A (en) *	1995-04-04	1997-12-16	Zymogenetics, Inc.	Native calcitonin mimetics
US5698672A (en) *	1995-04-04	1997-12-16	Zymogenetics, Inc.	Synthetic calcitonin mimetics
WO1997021448A1 (fr) *	1995-12-13	1997-06-19	Dullatur Limited	Preparation de calcitonine
GB9614235D0 (en) *	1996-07-06	1996-09-04	Danbiosyst Uk	Composition for enhanced uptake of polar drugs from mucosal surfaces
US7030082B2 (en) *	2001-09-07	2006-04-18	Nobex Corporation	Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4151276A (en) *	1975-05-12	1979-04-24	Armour Pharmaceutical Company	Method of suppressing gastric acid secretion by the oral administration of calcitonin
GB2127689B (en) *	1982-10-05	1986-07-09	Sandoz Ltd	Calcitonin inhalation compositions
AU572815B2 (en) *	1982-12-29	1988-05-19	Armour Pharmaceutical Company	Pharmaceutical calcitonin compositions for intranasal application
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
JPS61194034A (ja) *	1985-02-25	1986-08-28	Teijin Ltd	経鼻投与用粉末状組成物
HU203204B (en) *	1987-09-15	1991-06-28	Sandoz Ag	Process for producing suppository containing calcitonin and taurocholic acid
DK163689A (da) *	1988-04-08	1989-10-30	Sandoz Ag	Peptidderivater
HU206367B (en) *	1988-04-30	1992-10-28	Sandoz Ag	Process for producing acid addition salts of steroid carboxylic acid-amidated taurine and glycine, as well as pharmaceutical compositions comprising such salts
JP2911496B2 (ja) *	1989-09-11	1999-06-23	帝國製薬株式会社	生理活性ポリペプチド含有高吸収性経膣剤
DE69001991T2 (de) *	1989-11-16	1993-09-23	Phidea Spa	Fluessige arzneimittel zur nasalen anwendung, die ein polypeptid als wirksubstanz enthalten.

1992
- 1992-07-10 DE DE4222647A patent/DE4222647A1/de not_active Withdrawn
- 1992-07-13 GB GB9214830A patent/GB2257908B/en not_active Expired - Fee Related
- 1992-07-13 CH CH2194/92A patent/CH685600A5/de not_active IP Right Cessation
- 1992-07-13 BE BE9200650A patent/BE1007752A5/fr not_active IP Right Cessation
- 1992-07-13 FR FR9208675A patent/FR2682598B1/fr not_active Expired - Fee Related
- 1992-07-14 JP JP4186621A patent/JPH05194260A/ja active Pending
- 1992-07-14 IT ITRM920535A patent/IT1263222B/it active IP Right Grant

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6228836B1 (en)	1997-04-14	2001-05-08	Mitsubishi-Tokyo Pharmaceuticals, Inc.	Permucous preparation

Also Published As

Publication number	Publication date
BE1007752A5 (fr)	1995-10-17
FR2682598B1 (fr)	1996-04-05
ITRM920535A1 (it)	1994-01-14
FR2682598A1 (fr)	1993-04-23
DE4222647A1 (de)	1993-01-21
IT1263222B (it)	1996-08-05
ITRM920535A0 (it)	1992-07-14
GB9214830D0 (en)	1992-08-26
GB2257908A (en)	1993-01-27
GB2257908B (en)	1995-12-20
CH685600A5 (de)	1995-08-31

Publication	Publication Date	Title
US5578567A (en)	1996-11-26	Nasal pharmaceutical composition
RU2327484C2 (ru)	2008-06-27	Фармацевтическая композиция для назального всасывания
US5089482A (en)	1992-02-18	Pharmaceutical compositions for nasal administration containing steroid hormones and dimethyl-β-cyclodextrin
US5482706A (en)	1996-01-09	Transmucosal therapeutic composition
JP3549542B2 (ja)	2004-08-04	経口用ペプチド薬剤
US5011678A (en)	1991-04-30	Composition and method for administration of pharmaceutically active substances
WO1997006813A1 (fr)	1997-02-27	Preparation pour muqueuses a base de peptides a activite physiologique
Lee et al.	1994	The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer
US5183802A (en)	1993-02-02	Pharmaceutical compositions for intranasal administration of calcitonin
JPH10114645A (ja)	1998-05-06	経鼻投与用製剤
JPH0768149B2 (ja)	1995-07-26	鼻腔内投与用調製剤およびその製法
JPH05508616A (ja)	1993-12-02	治療用エアロゾル剤
EP1643970A2 (fr)	2006-04-12	Compositions et procedes d'une meilleure administration d'hormone de croissance par voie muqueuse
Nagai et al.	2024	Bioadhesive dosage forms for nasal administration
JPH05194260A (ja)	1993-08-03	ペプチド組成物
IL133176A (en)	2006-08-01	Pharmaceutical preparations containing peptides in a low solubility vessel in a physiological medium
EP0540631A1 (fr)	1993-05-12	Preparations medicamenteuses transmuqueuses et administration de telles preparations par voie transmuqueuse
JPH04230223A (ja)	1992-08-19	ソマトスタチン吸収改善医薬組成物、その製法および用途
WO1992016196A1 (fr)	1992-10-01	Composition renfermant un peptide pour administration nasale
IE83304B1 (en)		Pharmaceutical compositions comprising calcitonin
JPS62207226A (ja)	1987-09-11	経鼻投与用製剤
JPH05170664A (ja)	1993-07-09	安定なペプチド医薬組成物
JP3123100B2 (ja)	2001-01-09	吸収促進剤
JPS63243033A (ja)	1988-10-07	経鼻投与組成物
JP3824023B2 (ja)	2006-09-20	生理活性ペプチドを含有する経粘膜投与製剤

JPH05194260A - ペプチド組成物 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (4)

Publications (1)

Family

ID=26299234

Family Applications (1)

Country Status (7)

Cited By (1)

Families Citing this family (5)

Family Cites Families (10)

Cited By (1)

Also Published As

Similar Documents